Inhibitex to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
February 09 2011 - 4:26PM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell
Plumb, president and chief executive officer, will present an
overview of the Company and an update of its pipeline of
differentiated antiviral compounds at the Leerink Swann Hot Topics
in Therapeutics Roundtable Conference on February 16, 2011 at 3:20
PM (EST). The conference is being held at The Roosevelt Hotel in
New York, NY. The presentation will be simultaneously webcast and
can be accessed by visiting the Investors section of the Inhibitex
website at www.inhibitex.com. Shortly following the live
webcast, a replay will also be available on the Company
website.
About Inhibitex
Inhibitex, Inc., is a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s clinical-stage pipeline includes FV-100, a
nucleoside inhibitor in Phase II for the treatment of shingles, and
INX-189, a nucleotide polymerase inhibitor in Phase 1b for the
treatment of chronic hepatitis C infections. The Company also has
additional HCV nucleotide polymerase inhibitors in preclinical
development and has licensed the use of its proprietary MSCRAMM®
protein platform to Pfizer for the development of staphylococcal
vaccines. For additional information about the Company, please
visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024